Sanjiv.Parant.

- Base business expected to grow at approximately 25% year-on-year. - HAL JV projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26. - Prague JV operational with order flow expected to increase post logistical issues resolution; guidance uncertain due to logistics. - EBITDA margins impacted currently by high logistics costs but expected to improve as issues resolve. - No major incremental CAPEX anticipated beyond ongoing Rs. 10-12 crores spread over FY ‘25 and into next year for upgrades and regulatory compliance. - Export to domestic sales ratio: base business maintains 70% export, 30% domestic; with HAL JV, company aims for a balanced 50:50. - Challenges include geopolitical risks like Middle East tensions impacting logistics and markets. - Profit growth supported by strategic partnerships, product portfolio expansion, geographic diversification, and therapeutic area expansion in oncology and hormones (long-term).

- The Prague joint venture is partially operational with one small order executed in the European region. - Full operational speed for the Prague project is expected by end of August or September 2024, which will reflect in the order flow. - The company is currently in discussions for potential customers in Europe, Middle East (Saudi Arabia, UAE), and some African countries, but these opportunities are preliminary and impacted by logistics issues. - Hindustan Antibiotics Limited (HAL) joint venture is on track for commercial operations starting mid-October 2024. - No specific numeric order book or pending orders disclosed; the company highlighted uncertainty mainly due to logistics impacting Prague order flow. - The company expects order flow to improve as logistical issues resolve and new partnerships or government projects materialize later in FY 2025.

- Currently, Sanjivani Paranteral Limited has no debt on its books and plans to maintain a debt-free status. - There are no ongoing plans or requirements for new debt funding. - Regarding equity or other funding for future investments, no additional funds are needed at present. - Recent projects mentioned were funded earlier in January through a preferential equity raise, as disclosed in Stock Exchange documents. - No immediate fundraising activities are planned since existing funds cover current projects, and no new opportunities requiring funding have been identified.

- The company currently does not require additional funds for projects; recent investments were raised through a preferential raise in January. - For the base business growth (around 20-25% YoY), no major incremental CAPEX is expected beyond ongoing maintenance and upgrades. - Planned CAPEX of Rs. 10-12 crores is for basic upgrades and regulatory inspections, spread over this and next financial year, not as an annual recurring expense. - The HAL Joint Venture has a development timeline of 9-12 months for production start, with commercial operations expected by October 2024. - The Prague JV is partially operational, with full-scale operations anticipated by end of August or September 2024. - The company is exploring strategic partnerships, mainly with government PSUs and potential collaborations in oncology and hormone therapeutic areas, though no immediate new collaborations confirmed.

- Base business expected to grow at approximately 25% year-on-year. - HAL joint venture projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26. - Prague joint venture operational with initial orders executed; full operational capacity expected by end of August or September 2024. - Growth from strategic partnerships with five state PSUs and potential expansion via Public-Private Partnership (PPP) models. - Expansion into new geographies including Africa, Central America, Middle East, and Latin America. - Focus on complex products and higher value-addition segments, with plans to grow injectable segment alongside nutraceuticals via Prague. - Logistics and geopolitical uncertainty (e.g., Middle East tensions) present challenges affecting order flow and costs. - No major immediate funding required; prior preferential raise funded January 2024 projects.